References for Table III.

1. Fukata, Y. et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 313, 1792-5 (2006).
2. Makino, C., Shibata, H., Ninomiya, H., Tashiro, N. & Fukumaki, Y. Identification of single-nucleotide polymorphisms in the human N-methyl-D-aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr Genet 15, 215-21 (2005).
3. Hakak, Y. et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98, 4746-51 (2001).
4. Le-Niculescu, H. et al. Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 144B, 129-58 (2007).
5. Delgado, I. J., Kim, D. S., Thatcher, K. N., LaSalle, J. M. & Van den Veyver, I. B. Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients. BMC Med Genet 7, 61 (2006).
6. Browne, D. L. et al. Identification of two new KCNA1 mutations in episodic ataxia/myokymia families. Hum Mol Genet 4, 1671-2 (1995).
7. Weber, P., Bartsch, U., Schachner, M. & Montag, D. Na,K-ATPase subunit beta1 knock-in prevents lethality of beta2 deficiency in mice. J Neurosci 18, 9192-203 (1998).
8. Lenzen, K. P. et al. Supportive evidence for an allelic association of the human KCNJ10 potassium channel gene with idiopathic generalized epilepsy. Epilepsy Res 63, 113-8 (2005).
9. Zhang, J. et al. Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem 282, 15778-89 (2007).
10. Buono, R. J. et al. Association between variation in the human KCNJ10 potassium ion channel gene and seizure susceptibility. Epilepsy Res 58, 175-83 (2004).
11. Conti, L. et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 3, e283 (2005).
12. Konradi, C. et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61, 300-8 (2004).
13. Silberberg, G. et al. Stargazin involvement with bipolar disorder and response to lithium treatment. Pharmacogenet Genomics 18, 403-12 (2008).
14. Xing, G. et al. Decreased prefrontal CaMKII alpha mRNA in bipolar illness. Neuroreport 13, 501-5 (2002).
15. Kyosseva, S. V. Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28, 997-1006 (2004).
16. Kyosseva, S. V. et al. Mitogen-activated protein kinases in schizophrenia. Biol Psychiatry 46, 689-96 (1999).
17. Novak, G., Seeman, P. & Tallerico, T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse 59, 61-8 (2006).
18. Dwivedi, Y. et al. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 77, 916-28 (2001).
19. Gulesserian, T., Kim, S. H., Fountoulakis, M. & Lubec, G. Aberrant expression of centractin and capping proteins, integral constituents of the dynactin complex, in fetal down syndrome brain. Biochem Biophys Res Commun 291, 62-7 (2002).
20. Jordanova, A. et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 126, 590-7 (2003).
21. Holmes, S. E. et al. Disruption of the clathrin heavy chain-like gene (CLTCL) associated with features of DGS/VCFS: a balanced (21;22)(p12;q11) translocation. Hum Mol Genet 6, 357-67 (1997).
22. Carter, C. J. eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia? Schizophr Bull 33, 1343-53 (2007).
23. Clinton, S. M. & Meador-Woodruff, J. H. Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. Neuropsychopharmacology 29, 1353-62 (2004).

24. Toyooka, K. et al. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 83, 797-806 (2002).
25. Georgiou, D. M. et al. A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics 4, 93-6 (2002).
26. Miltenberger-Miltenyi, G. et al. Clinical and electrophysiological features in Charcot-Marie-Tooth disease with mutations in the NEFL gene. Arch Neurol 64, 966-70 (2007).
27. Cluskey, S. & Ramsden, D. B. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol 54, 386-92 (2001).
28. Lee, I. et al. A single gene network accurately predicts phenotypic effects of gene perturbation in Caenorhabditis elegans. Nat Genet 40, 181-8 (2008).
29. Szatmari, P. et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 39, 319-28 (2007).
30. Mirnics, K., Middleton, F. A., Marquez, A., Lewis, D. A. & Levitt, P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67 (2000).
31. Tarpey, P. et al. Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet 75, 318-24 (2004).
32. Koene, S. et al. Major depression in adolescent children consecutively diagnosed with mitochondrial disorder. J Affect Disord (2008).
33. Dracheva, S. et al. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158, 1400-10 (2001).
34. Svaasand, E. K., Aasly, J., Landsem, V. M. & Klungland, H. Altered expression of PGK1 in a family with phosphoglycerate kinase deficiency. Muscle Nerve 36, 679-84 (2007).
35. Pickard, B. S. et al. Candidate psychiatric illness genes identified in patients with pericentric inversions of chromosome 18. Psychiatr Genet 15, 37-44 (2005).
36. Matigian, N. et al. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Mol Psychiatry 12, 815-25 (2007).
37. Pennington, K. et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13, 1102-17 (2008).
38. Kutsuwada, T. et al. Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice. Neuron 16, 333-44 (1996).
39. Yao, W. D. et al. Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41, 625-38 (2004).
40. Sokolov, B. P. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J Neuropsychopharmacol 10, 547-55 (2007).
41. Vawter, M. P. et al. Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 67, 41-52 (2004).
42. Jamain, S. et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34, 27-9 (2003).
43. Trotter, J. L., Hickey, W. F., van der Veen, R. C. & Sulze, L. Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. J Neuroimmunol 33, 55-62 (1991).
44. Klein, L., Klugmann, M., Nave, K. A., Tuohy, V. K. & Kyewski, B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med 6, 56-61 (2000).
45. Chou, Y. K. et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 38, 105-13 (1992).
46. O'Connor, J. A. & Hemby, S. E. Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia. Schizophr Res 97, 277-88 (2007).
47. Magri, C. et al. Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. Am J Med Genet B Neuropsychiatr Genet 147B, 745-53 (2008).

48. Eastwood, S. L. et al. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 29, 211-23 (1995).
49. Komiyama, N. H. et al. SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and learning in the complex with postsynaptic density 95 and NMDA receptor. J Neurosci 22, 9721-32 (2002).
50. Ibrahim, H. M. et al. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 157, 1811-23 (2000).
51. Whitham, R. H. et al. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. J Immunol 146, 101-7 (1991).
52. Bongarzone, E. R. et al. Identification of a new exon in the myelin proteolipid protein gene encoding novel protein isoforms that are restricted to the somata of oligodendrocytes and neurons. J Neurosci 19, 8349-57 (1999).
53. Bruno, R. et al. Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus. Eur J Immunol 32, 2737-47 (2002).
54. Jewtoukoff, V., Amzazi, S., Lebar, R., Bach, M. A. & Marche, P. N. T-cell receptor identification of an oligodendrocyte-specific autoreactive cytotoxic T-cell clone without self restriction. Scand J Immunol 36, 893-8 (1992).
55. Wakabayashi, K. et al. Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease. Neurobiol Aging 20, 287-95 (1999).
56. Pellegrini-Giampietro, D. E., Bennett, M. V. & Zukin, R. S. AMPA/kainate receptor gene expression in normal and Alzheimer's disease hippocampus. Neuroscience 61, 41-9 (1994).
57. Yasuda, R. P. et al. Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study. Brain Res 678, 161-7 (1995).
58. Aronica, E., Dickson, D. W., Kress, Y., Morrison, J. H. & Zukin, R. S. Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience 82, 979-91 (1998).
59. Eder, P., Reinprecht, I., Schreiner, E., Skofitsch, G. & Windisch, M. Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats. Histochem J 33, 605-12 (2001).
60. Gorman, M. P. et al. Steroid-responsive neurologic relapses in a child with a proteolipid protein-1 mutation. Neurology 68, 1305-7 (2007).
61. Grigorenko, E. et al. Changes in glutamate receptor subunit composition in hippocampus and cortex in patients with refractory epilepsy. J Neurol Sci 153, 35-45 (1997).
62. Babb, T. L. et al. Glutamate AMPA receptors in the fascia dentata of human and kainate rat hippocampal epilepsy. Epilepsy Res 26, 193-205 (1996).
63. Gerber, D. J. et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A 100, 8993-8 (2003).
64. Beveridge, N. J. et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17, 1156-68 (2008).
65. Cumming, R. C., Dargusch, R., Fischer, W. H. & Schubert, D. Increase in expression levels and resistance to sulfhydryl oxidation of peroxiredoxin isoforms in amyloid beta-resistant nerve cells. J Biol Chem 282, 30523-34 (2007).
66. Ganor, Y. et al. Antibodies to glutamate receptor subtype 3 (GluR3) are found in some patients suffering from epilepsy as the main disease, but not in patients whose epilepsy accompanies antiphospholipid syndrome or Sneddon's syndrome. Autoimmunity 38, 417-24 (2005).
67. Watson, R. et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63, 43-50 (2004).
68. Levite, M., Fleidervish, I. A., Schwarz, A., Pelled, D. & Futerman, A. H. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J Autoimmun 13, 61-72 (1999).
69. Levite, M. & Hermelin, A. Autoimmunity to the glutamate receptor in mice--a model for Rasmussen's encephalitis? J Autoimmun 13, 73-82 (1999).

70. Moga, D. E. et al. Glutamate receptor subunit 3 (GluR3) immunoreactivity delineates a subpopulation of parvalbumin-containing interneurons in the rat hippocampus. J Comp Neurol 462, 15-28 (2003).
71. Rembach, A. et al. Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J Neurosci Res 77, 573-82 (2004).
72. Fang, J., Nakamura, T., Cho, D. H., Gu, Z. & Lipton, S. A. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A 104, 18742-7 (2007).
73. Wu, Y. et al. Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans. Proc Natl Acad Sci U S A 104, 18163-8 (2007).
74. Julien, J. P. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104, 581-91 (2001).
75. Motazacker, M. M. et al. A defect in the ionotropic glutamate receptor 6 gene (GRIK2) is associated with autosomal recessive mental retardation. Am J Hum Genet 81, 792-8 (2007).
76. Kaukonen, J. et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 289, 782-5 (2000).
77. Behan, A., Byrne, C., Dunn, M. J., Cagney, G. & Cotter, D. R. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry (2008).
78. Bickel, S., Lipp, H. P. & Umbricht, D. Impaired attentional modulation of auditory evoked potentials in N-methyl-D-aspartate NR1 hypomorphic mice. Genes Brain Behav 6, 558-68 (2007).
79. Potkin, S. G. et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull 35, 96-108 (2009).
80. Mundo, E. et al. Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol Psychiatry 8, 241-5 (2003).
81. Begni, S. et al. Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol Psychiatry 53, 617-9 (2003).
82. Suh, J. G., Ryoo, Z. W., Won, M. H., Oh, Y. S. & Kang, T. C. Differential alteration of NMDA receptor subunits in the gerbil dentate gyrus and subiculum following seizure. Brain Res 904, 104-11 (2001).
83. Smith, R. E., Haroutunian, V., Davis, K. L. & Meador-Woodruff, J. H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 158, 1393-9 (2001).
84. Arning, L. et al. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 122, 175-82 (2007).
85. Cardoso, C. et al. Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. Am J Hum Genet 72, 918-30 (2003).
86. Martucci, L. et al. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res 84, 214-21 (2006).
87. Abdolmaleky, H. M., Thiagalingam, S. & Wilcox, M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 5, 149-60 (2005).
88. Fallin, M. D. et al. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 77, 918-36 (2005).
89. Knuesel, M. et al. Identification of novel protein-protein interactions using a versatile mammalian tandem affinity purification expression system. Mol Cell Proteomics 2, 1225-33 (2003).
90. Arzberger, T., Krampfl, K., Leimgruber, S. & Weindl, A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study. J Neuropathol Exp Neurol 56, 440-54 (1997).